Watson Oxytrol Launch Planned For Mid-2002 As Firm Shifts Focus To Brands
Executive Summary
Watson plans to use a marketing partner or contract sales organization to launch its overactive bladder transdermal patch Oxytrol (oxybutynin)
You may also be interested in...
Watson Oxytrol Launch To Focus On Specialists; CSO To Target Primary Care
Watson's launch of the Oxytrol overactive bladder transdermal patch will be modeled after Alza's Ditropan XL market entry
Watson Oxytrol Launch To Focus On Specialists; CSO To Target Primary Care
Watson's launch of the Oxytrol overactive bladder transdermal patch will be modeled after Alza's Ditropan XL market entry
Watson Oxytrol Approval Expected In 2003; Patch Is “Not Approvable” At FDA
Watson Pharmaceuticals expects the overactive bladder patch Oxytrol to be cleared by FDA in the first quarter of 2003, following receipt of a "not approvable" letter March 26